Incidence and Risk Factors for Postoperative Venous Thromboembolism After Gender Affirming Vaginoplasty: A Retrospective Analysis of a Large Insurance Claims Database.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 04 05 2023
revised: 20 07 2023
accepted: 14 08 2023
medline: 11 12 2023
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

To investigate the incidence and associated risk factors of venous thromboembolism (VTE) after gender affirming vaginoplasty. We searched International Business Machines Corporation (IBM) Marketscan, a commercial claims database, for Current Procedural Terminology and International Classification of Diseases (ICD) procedure codes to identify patients who underwent gender affirming vaginoplasty from 2011-2020. We quantified deep venous thrombosis and pulmonary embolism using ICD-9 and ICD-10 codes found within 90 days after surgery. Univariate and multivariate analyses were performed to establish association between VTE events and age, residency location, and comorbidities. We identified 1588 patients who underwent gender affirming vaginoplasty. Overall, 1.1% of patients experienced a VTE within 90 days following surgery. Patients who experienced postoperative VTE were older, more likely to have had a prior VTE, less likely to be from an urban area, and more likely to have a higher Charlson Comorbidity Index score. Among patients with postoperative VTE, 47.1% had previous VTE. Among patients without a postoperative VTE, 1.3% had previous VTE. In patients undergoing gender affirming vaginoplasty, the incidence of postoperative VTE was 1.1%. Older age, rurality, increased comorbidities, and prior VTE were associated with increased risk of postoperative VTE. Current guidelines do not recommend cessation of gender affirming hormone therapy (GAHT) prior to vaginoplasty. Further research is needed to evaluate if certain high-risk patients would benefit from perioperative adjustment of GAHT or perioperative VTE prophylaxis.

Identifiants

pubmed: 37774849
pii: S0090-4295(23)00830-0
doi: 10.1016/j.urology.2023.08.041
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

95-100

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare no conflict of interest.

Auteurs

Liem Snyder (L)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: liem.snyder@hsc.utah.edu.

Kevin J Hebert (KJ)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: kevin.hebert@hsc.utah.edu.

Joshua J Horns (JJ)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: Joshua.horns@hsc.utah.edu.

Jessica Schardein (J)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: u6043075@hsc.utah.edu.

Benjamin J McCormick (BJ)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: mccormick@hsc.utah.edu.

Jae Downing (J)

Oregon Health and Science University, Portland, OR. Electronic address: jaecorman@gmail.com.

Geolani W Dy (GW)

Oregon Health and Science University, Portland, OR. Electronic address: dy@ohsu.edu.

Isak Goodwin (I)

Division of Plastic Surgery, University of Utah, Salt Lake City, UT. Electronic address: isak.goodwin@hsc.utah.edu.

Cori Agarwal (C)

Division of Plastic Surgery, University of Utah, Salt Lake City, UT. Electronic address: cori.agarwal@hsc.utah.edu.

James M Hotaling (JM)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: jim.hotaling@hsc.utah.edu.

Jeremy B Myers (JB)

Division of Urology, University of Utah, Salt Lake City, UT. Electronic address: Jeremy.myers@hsc.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH